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Signaling from class I phosphoinositide 3-kinase (PI3K) is often deregulated in leukemia and lymphoma, but
which isoforms are involved in T cell acute lymphoblastic leukemia (T-ALL) was not known. In this issue of
Cancer Cell, Subramaniam et al. show that T-ALL can be tamed by inhibiting g and d PI3K isoforms.Class I phosphoinositide 3-kinase (PI3K)
activate fundamental pathways control-
ling survival, proliferation, and metabo-
lism and thus represent crucial players in
cancer development. Despite activating
similar signaling cascades, the four
human class I PI3Ks, each of which is
composed of a regulatory subunit and
one of the four p110 catalytic subunits
(p110a, b, g, and d), show non-redundant
roles in oncogenesis. For example,
PIK3CA, the gene encoding p110a, is
frequently mutated in cancers originat-
ing from different organs, including the
mammary gland, colon, prostate, and
brain (Wong et al., 2010). On the contrary,
the p110b isoform does not accumulate
mutations but plays a critical role in
specific tumors, such as PTEN-deficient
(Jia et al., 2008) or ErbB2-driven (Ciraolo
et al., 2008) cancers. Similarly, the leuko-
cyte-specific p110d isoform is usually
intact in human cancers, yet it drives
B cell malignancies including chronic
lymphocytic leukemia and mantle cell
lymphoma (So and Fruman, 2012).
The fourth PI3K catalytic isoform,
p110g, is mainly expressed in leukocytes,
and its role in cancer is only now starting
to emerge. In white blood cells, p110g
usually drives G protein coupled receptor
(GPCR)-mediated responses and shapes
various forms of inflammatory reactions
by controlling macrophage and neutrophil
migration to chemotactic cues (Ghigo
et al., 2010). Similar to p110d, p110g is
also highly expressed in B and T lympho-
cytes but with a role considered minor so
far, probably not affecting trafficking but
rather specific differentiation steps. In
T cell development, p110g and p110d
together control the b selection process,
allowing thymocytes to mature to thedouble positive (DP) stage. In these matu-
ration steps, p110d is required to modu-
late signals that originate from the pre-T
cell receptor (TCR) complex, whereas
p110g is necessary for signals that derive
from CXCR4 activation (Figure 1). Dele-
tion of PTEN from developing thymocytes
allows an unopposed activation of both
p110s, resulting in abnormal passage to
the DP stage in the absence of a mature
TCR as well as in the development of
T cell leukemia (So and Fruman, 2012).
Despite the ability of p110g to cause
transformation when overexpressed in
cultured cells (Kang et al., 2006), direct
evidence for its role in human cancer
was missing. The ability of PI3Kg to acti-
vate the classical PI3K pathway, trig-
gering AKT, GSK3, and S6K phosphoryla-
tion, was long considered a business
mainly for innate immunity aficionados.
Nonetheless, recent evidence indicates
that PI3Kg is a key player in the inflamma-
tory reactions that contribute to tumor
progression and spreading (Schmid
et al., 2011). In addition, PI3Kg has also
been found to drive, in immunocompro-
mised patients, angioproliferative tumors
induced by the Kaposi’s sarcoma-associ-
ated virus, where its oncoviral receptor
vGPCR couples to PI3Kg to induce AKT/
mTOR signaling (Martin et al., 2011).
The article by Subramaniam et al.
(2012) in this issue of Cancer Cell further
extends this notion and shows that
PI3Kg functions in concert with its cousin
PI3Kd to support development of T cell
acute lymphoblastic leukemia (T-ALL).
How did Subramaniam et al. (2012) dis-
cover these unexpected findings? They
reasoned that the PI3K/AKT signaling
pathway is frequently activated in T-ALL
driven by PTEN loss (found in aboutCancer Cel40% of T-ALL patients) rather than by
activating mutations of PIK3CA that
are found commonly in solid cancers
(Wong et al., 2010). Therefore, other class
I PI3Ks likely were involved in T-ALL.
Developing thymocytes are thought to
be the normal counterpart of transformed
T-ALL cells, and the activities of both
PI3Kd and PI3Kg are required to sustain
normal thymic development and thymo-
cyte survival (So and Fruman, 2012).
Thus, Subramaniam et al. (2012) set out
to define the PI3K isoform involved in
T-ALL by introducing null mutations in
Pik3cg and Pik3cd, which encode for
p110g and p110d respectively, in amouse
model of T-ALL induced by conditional
PTEN loss in T cells. To their surprise,
in strict similarity with normal T cell devel-
opment, both p110d and p110g were
necessary to sustain T-ALL development,
whereas single mutants had no antitumor
effect (Figure 1). Deletion of PTEN in the
absence of both p110d and p110g was
not associated with increased AKT phos-
phorylation, thus indicating a negligible
role for the other two class I PI3K iso-
forms, PI3Ka and PI3Kb, in the develop-
ment of either normal T cells or leukemia.
These findings are interesting for
several reasons. First, they reaffirm the
concept of a strong interconnection
between T cell development and T cell
leukemia, similarly to other T-ALL onco-
genes. For example, Notch1 plays crucial
roles in T cell differentiation and is
frequently mutated in T-ALL (Aifantis
et al., 2008). The essential PI3Kd and
PI3Kg signaling functions in T cell devel-
opment could thus be retained and ex-
ploited by leukemic cells. Second, these
results clearly show an additive role for

















Figure 1. Role of PI3Kd and PI3Kg Isoforms in the
Development of Normal Thymocytes and T-ALL
(Top) Signal transduction events leading to differentiation of
T cells from the double negative (DN) to the double positive
(DP) stage.
(Bottom) Loss of PTEN leads to unrestrained p110g and
d activity and T-ALL. The use of the drug CAL-130 inhibits
these two p110 PI3K isoforms, thus blocking T-ALL.
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a specific contribution of p110g
to the survival and growth of a
hematologic malignancy. This is
new, because the only PI3K isoform
thought to be involved in leukemia
and lymphomas so far was PI3Kd,
a direct effector of tyrosine phos-
phorylation events downstream of
CD28 and CD19 in T and B cells,
respectively. The involvement of
p110d in B cell tumors such as
chronic lymphocytic leukemia has
recently gained great attention, as
selective inhibitors such as CAL-
101 have provided encouraging
results in combined phase I/II clinical
trials with cases of full remission
(So and Fruman, 2012). Third, these
results pave the way for novel thera-
peutic targeting in T-ALL. Indeed,
Subramaniam et al. (2012) went on
to prove this point. They tested
derivative compounds of CAL-101
and found that CAL-130 works as
a specific dual inhibitor of p110g
and p110d. When given to mice,
CAL-130 closely reproduced the
thymic phenotype of double Pik3cg-
and Pik3cd null mutants. Strikingly,
and more importantly, CAL-130
prolonged survival of PTEN null
mice and reduced human T-ALL
growth by inducing apoptosis due
to a block of the AKT-mediated
survival pathway. Although further
experimentation and clinical trialsare required to fully access the efficacy
and toxicity, mice treated with the cur-
rently available compound did not show
major signs of toxicity. The future possi-
bility of treating patients with a p110g/
p110d dual inhibitor that in principle450 Cancer Cell 21, April 17, 2012 ª2012 Elsavoids the undesirable systemic effects
that may be linked to pan-PI3K inhibition,
such as diabetes, is particularly attractive.
Whether this approach can be widened
to other T lymphomas, which may also
depend on both p110g and p110d for theirevier Inc.growth, or if it is effective only in
PTEN-deficient T-ALL remains to
be established. Future studies will
likely better define the spectrum of
efficacy of PI3Kd and PI3Kg target-
ing in T-ALL with different genetic
defects as well as in a larger set of
hematological malignancies.REFERENCES
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